We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| Roche Holdings Ltd AG (QX) | USOTC:RHHBY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.19 | -0.60% | 31.60 | 31.56 | 31.84 | 31.69 | 31.49 | 31.66 | 1,752,108 | 21:10:12 |
From May 2021 to May 2024
By Colin Kellaher
Harpoon Therapeutics Inc. signed a supply agreement with Roche Holding AG under which Harpoon plans to add Roche's cancer drug Tecentriq to its HPN328 development program, Harpoon said Monday.
The clinical-stage immunotherapy company plans to evaluate HPN328 in combination with Tecentriq in patients with small cell lung cancer, it said.
The South San Francisco, Calif., would sponsor of the anticipated clinical trials, while Roche would supply Tecentriq, Harpoon said.
Harpoon shares, which closed Friday at $2.25, rose 6.7%, to $2.40, in premarket trading Monday.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
May 02, 2022 09:34 ET (13:34 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Roche (QX) Chart |
1 Month Roche (QX) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
